255 reports of this reaction
2.3% of all ENTACAPONE reports
#7 most reported adverse reaction
CONFUSIONAL STATE is the #7 most commonly reported adverse reaction for ENTACAPONE, manufactured by Ajanta Pharma USA Inc.. There are 255 FDA adverse event reports linking ENTACAPONE to CONFUSIONAL STATE. This represents approximately 2.3% of all 11,238 adverse event reports for this drug.
Patients taking ENTACAPONE who experience confusional state should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONFUSIONAL STATE is a less commonly reported adverse event for ENTACAPONE, but still significant enough to appear in the safety profile.
In addition to confusional state, the following adverse reactions have been reported for ENTACAPONE:
The following drugs have also been linked to confusional state in FDA adverse event reports:
CONFUSIONAL STATE has been reported as an adverse event in 255 FDA reports for ENTACAPONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONFUSIONAL STATE accounts for approximately 2.3% of all adverse event reports for ENTACAPONE, making it a notable side effect.
If you experience confusional state while taking ENTACAPONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.